Healthcare / Medical DistributionJakarta
$2290.00
-30.00 (-1.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 24%
FCF escenarios
weak_data · normalized FCF $446.4B · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
57/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.20T
P/E
8.0x
↓EV/EBITDA
4.5x
↓ROE
10.1%
↑Gross Margin
10.0%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.6%
FCF CAGR
—
FCF margin
1.8%
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $32.96T · net income $789.19B · FCF $602.26B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $32960.72B | $32960.72B | $30957.34B | $28507.87B | $28027.49B |
| Net Income | $789.19B | $789.19B | $741.77B | $688.50B | $847.53B |
| EBITDA | $1235.05B | $1235.05B | $1150.53B | $1072.75B | $1274.63B |
| EPS | 291.00 | 291.00 | 274.00 | 254.00 | 313.00 |
| Gross Margin | 10.0% | 10.0% | 9.9% | 10.2% | 10.6% |
| Operating Margin | 3.2% | 3.2% | 3.2% | 3.2% | 3.9% |
| Net Margin | 2.4% | 2.4% | 2.4% | 2.4% | 3.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Current Ratio | 2.09 | 2.09 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $602.26B | $602.26B | $446.44B | $219.60B | $-159.68B |
| Returns | |||||
| ROE | 10.1% | 10.1% | 9.8% | 9.5% | 11.9% |
| Valuation | |||||
| P/E | 8.01 | 8.01 | 8.76 | 10.39 | 8.69 |
| EV/EBITDA | 4.45 | 4.45 | 5.14 | 6.03 | 5.01 |
| P/B | 0.79 | 0.79 | 0.86 | 0.99 | 1.04 |
| Growth & Yield | |||||
| Revenue Growth | 6.5% | 6.5% | 8.6% | 1.7% | — |
| EPS Growth | 6.2% | 6.2% | 7.9% | -18.8% | — |
| Dividend Yield | 7.8% | 7.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-11.3%
EPS terminal req.
$203.20
Spread vs growth
17.5%
5Y implied EPS CAGR
-3.3%
EPS terminal req.
$245.87
Spread vs growth
9.5%
10Y implied EPS CAGR
3.1%
EPS terminal req.
$395.98
Spread vs growth
3.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.2%
Start / end P/E
8.8x → 7.9x
EPS bridge
274.00 → 291.00
Residual
-0.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.